TOP TEN perturbations for 1419_g_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1419_g_at
Selected probe(set): 210037_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1419_g_at (210037_s_at) across 6672 perturbations tested by GENEVESTIGATOR:
ulcerative colitis study 4 (inflamed) / normal colon mucosa tissue (IBS)
Relative Expression (log2-ratio):3.326582Number of Samples:8 / 17
| Experimental | ulcerative colitis study 4 (inflamed) |
| Mucosa biopsy samples derived from the descending colon from areas with macroscopic and microscopic signs of inflammation derived from patients with ulcerative colitis. | |
| Control | normal colon mucosa tissue (IBS) |
| Mucosa biopsies derived from the descending colon from patients with the diagnosis of irritable bowel syndrome due to normal test results in different investigations including colonoscopy. |
Crohn's disease study 10 / colorectal cancer study 13 (hypp. pol.)
Relative Expression (log2-ratio):3.0840054Number of Samples:4 / 11
| Experimental | Crohn's disease study 10 |
| Colon biopsies derived from patients with Crohn's disease. | |
| Control | colorectal cancer study 13 (hypp. pol.) |
| Colon biopsies derived from patients with hyperplastic polyps. |
ulcerative colitis study 5 (baseline; responder) / normal colon mucosa tissue
Relative Expression (log2-ratio):2.988823Number of Samples:8 / 6
| Experimental | ulcerative colitis study 5 (baseline; responder) |
| Colonic mucosal biopsies derived from ulcerative colitis patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication. | |
| Control | normal colon mucosa tissue |
| Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening. |
ulcerative colitis study 5 (baseline; non-responder) / normal colon mucosa tissue
Relative Expression (log2-ratio):2.9634228Number of Samples:16 / 6
| Experimental | ulcerative colitis study 5 (baseline; non-responder) |
| Colonic mucosal biopsies derived from ulcerative colitis patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication. | |
| Control | normal colon mucosa tissue |
| Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening. |
ulcerative colitis study 11 / normal colon tissue
Relative Expression (log2-ratio):2.834549Number of Samples:3 / 3
| Experimental | ulcerative colitis study 11 |
| Colon biopsies derived from patients with ulcerative colitis. | |
| Control | normal colon tissue |
| Colon biopsies derived from healthy controls. |
ulcerative colitis study 11 / colorectal cancer study 13 (hypp. pol.)
Relative Expression (log2-ratio):2.800974Number of Samples:3 / 11
| Experimental | ulcerative colitis study 11 |
| Colon biopsies derived from patients with ulcerative colitis. | |
| Control | colorectal cancer study 13 (hypp. pol.) |
| Colon biopsies derived from patients with hyperplastic polyps. |
ulcerative colitis study 29 (infliximab; 5mg/kg; responder; 30wk) / ulcerative colitis study 29 (infliximab; 5mg/kg; non-responder; 30wk)
Relative Expression (log2-ratio):-2.7245464Number of Samples:6 / 3
| Experimental | ulcerative colitis study 29 (infliximab; 5mg/kg; responder; 30wk) |
| Colonic mucosal biopsies from ulcerative colitis patients who are responders to infliximab treatment at timepoint 30 weeks (during maintenance phase). At baseline patients had a diagnosis of moderately to severe active ulcerative colitis (Mayo score of 6 to 12). Biopsies were taken 30 weeks after patients received intravenous infusions of 5 mg infliximab per kg body weight. During induction phase (week 0-8) patients received infusions at weeks 0, 2, and 6 and during maintenance phase (weeks 8-46) patients received infusions every 8 weeks beginning at week 14. Clinical response was defined as a decrease from baseline in the total Mayo score of at least three points and at least at 30%, with an accompanying decrease in the subscore for rectal bleeding of at least one point or an absolute subscore for rectal bleeding of 0 or 1. Biopsies were collected from lesions 15 to 20 cm from the anal verge. ATC code: | |
| Control | ulcerative colitis study 29 (infliximab; 5mg/kg; non-responder; 30wk) |
| Colonic mucosal biopsies from ulcerative colitis patients who are non-responders to infliximab treatment at timepoint 30 weeks (during maintenance phase). At baseline patients had a diagnosis of moderately to severe active ulcerative colitis (Mayo score of 6 to 12). Biopsies were taken 30 weeks after patients received intravenous infusions of 5 mg infliximab per kg body weight. During induction phase (week 0-8) patients received infusions at weeks 0, 2, and 6 and during maintenance phase (weeks 8-46) patients received infusions every 8 weeks beginning at week 14. Clinical response was defined as a decrease from baseline in the total Mayo score of at least three points and at least at 30%, with an accompanying decrease in the subscore for rectal bleeding of at least one point or an absolute subscore for rectal bleeding of 0 or 1. Biopsies were collected from lesions 15 to 20 cm from the anal verge. ATC code: |
Crohn's disease study 10 / colorectal cancer study 13 (crc)
Relative Expression (log2-ratio):2.6617203Number of Samples:4 / 7
| Experimental | Crohn's disease study 10 |
| Colon biopsies derived from patients with Crohn's disease. | |
| Control | colorectal cancer study 13 (crc) |
| Colon biopsies derived from patients with colorectal carcinoma. |
ulcerative colitis study 12 / normal colorectal tissue
Relative Expression (log2-ratio):2.6598854Number of Samples:7 / 8
| Experimental | ulcerative colitis study 12 |
| Tissue biopsy samples derived from patients diagnosed with severe active ulcerative colitis localized in different colorectal regions . | |
| Control | normal colorectal tissue |
| Normal tissue biopsies derived from different colorectal regions of healthy controls. |
ulcerative colitis study 5 (infliximab; 5mg/kg; responder) / ulcerative colitis study 5 (baseline; responder)
Relative Expression (log2-ratio):-2.6275215Number of Samples:7 / 8
| Experimental | ulcerative colitis study 5 (infliximab; 5mg/kg; responder) |
| Colonic mucosal biopsies from ulcerative colitis patients who are responders to infliximab treatment, taken after the first intravenous infusion of 5 mg infliximab per kg body weight. Biopsies were taken 4 weeks after the first infliximab infusion in case of a single infusion and at 6 weeks if patients received a loading dose of infliximab at weeks 0, 2 and 6. The response to infliximab was assessed at 4 to 6 weeks after the first infliximab treatment, respectively. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication. ATC code: | |
| Control | ulcerative colitis study 5 (baseline; responder) |
| Colonic mucosal biopsies derived from ulcerative colitis patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication. |